Equities Analysts Issue Forecasts for Envoy Medical Q3 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Equities researchers at Brookline Capital Management issued their Q3 2024 EPS estimates for shares of Envoy Medical in a report released on Monday, October 14th. Brookline Capital Management analyst T. Bussian forecasts that the company will post earnings per share of ($0.27) for the quarter. Brookline Capital Management has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.22) per share. Brookline Capital Management also issued estimates for Envoy Medical’s Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.56) EPS.

Separately, Ascendiant Capital Markets raised their price target on shares of Envoy Medical from $8.50 to $8.75 and gave the company a “buy” rating in a research report on Tuesday, September 3rd.

Envoy Medical Price Performance

Shares of COCH stock opened at $2.73 on Wednesday. Envoy Medical has a 52 week low of $0.75 and a 52 week high of $11.46. The firm has a 50 day moving average of $3.01 and a two-hundred day moving average of $3.17.

Envoy Medical (NASDAQ:COCH) last posted its earnings results on Monday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.08 million.

Hedge Funds Weigh In On Envoy Medical

A hedge fund recently bought a new stake in Envoy Medical stock. WealthTrust Asset Management LLC purchased a new stake in Envoy Medical, Inc. (NASDAQ:COCH) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 11,316 shares of the company’s stock, valued at approximately $44,000. WealthTrust Asset Management LLC owned 0.06% of Envoy Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 8.59% of the company’s stock.

About Envoy Medical

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.